Motzer RJ - Search Results

1

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK. Motzer RJ, et al. N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989. N Engl J Med. 2013. PMID: 23964934 Free article. Clinical Trial.

2

Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.

Motzer RJ, Nanus DM, O'Moore P, Scher HI, Bajorin DF, Reuter V, Tong WP, Iversen J, Louison C, Albino AP, et al. Motzer RJ, et al. Cancer Res. 1992 Oct 15;52(20):5775-9. Cancer Res. 1992. PMID: 1394202 Clinical Trial.

3

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.

Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, Nanus D, O'Moore P, Marathias K, Bosl GJ. Ilson DH, et al. Among authors: motzer rj. J Clin Oncol. 1992 Jul;10(7):1124-30. doi: 10.1200/JCO.1992.10.7.1124. J Clin Oncol. 1992. PMID: 1607918 Clinical Trial.

4

Phase II trial of Didemnin B in patients with advanced renal cell carcinoma.

Motzer R, Scher H, Bajorin D, Sternberg C, Bosl GJ. Motzer R, et al. Invest New Drugs. 1990 Nov;8(4):391-2. doi: 10.1007/BF00198598. Invest New Drugs. 1990. PMID: 2084073 Clinical Trial.

5

Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro.

Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Nanus DM. Motzer RJ, et al. J Clin Oncol. 1995 Aug;13(8):1950-7. doi: 10.1200/JCO.1995.13.8.1950. J Clin Oncol. 1995. PMID: 7636535 Clinical Trial.

6

Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma.

Law TM, Mencel P, Motzer RJ. Law TM, et al. Among authors: motzer rj. Invest New Drugs. 1994;12(4):323-5. doi: 10.1007/BF00873048. Invest New Drugs. 1994. PMID: 7775134 Clinical Trial.

7

Phase II trial of topotecan in patients with advanced renal cell carcinoma.

Law TM, Ilson DH, Motzer RJ. Law TM, et al. Among authors: motzer rj. Invest New Drugs. 1994;12(2):143-5. doi: 10.1007/BF00874445. Invest New Drugs. 1994. PMID: 7860232 Clinical Trial.

8

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.

Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Minasian LM, et al. Among authors: motzer rj. J Clin Oncol. 1993 Jul;11(7):1368-75. doi: 10.1200/JCO.1993.11.7.1368. J Clin Oncol. 1993. PMID: 8315435 Clinical Trial.

9

Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.

Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF. Law TM, et al. Among authors: motzer rj. Cancer. 1995 Sep 1;76(5):824-32. doi: 10.1002/1097-0142(19950901)76:5<824::aid-cncr2820760517>3.0.co;2-n. Cancer. 1995. PMID: 8625186 Clinical Trial.

10

Renal-cell carcinoma.

Motzer RJ, Bander NH, Nanus DM. Motzer RJ, et al. N Engl J Med. 1996 Sep 19;335(12):865-75. doi: 10.1056/NEJM199609193351207. N Engl J Med. 1996. PMID: 8778606 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

606 results

Search Page